- Optimi Health (CSE:OPTI) has revealed it has completed the inaugural export of its GMP-validated MDMA capsules to Australia to treat post-traumatic stress disorder
- The export has been made under Australia’s Authorised Prescriber Scheme
- The first set of patients will begin MDMA-assisted therapy capsules in the coming weeks
- Shares of Optimi Health are up 1.67 per cent to C$0.30 as of 10:05 am ET
Optimi Health (CSE:OPTI) has revealed it has completed the inaugural export of its GMP-validated MDMA capsules to Australia to treat post-traumatic stress disorder (PTSD) under Australia’s Authorised Prescriber Scheme.
The company stated in a news release that the first set of patients will begin MDMA-assisted therapy capsules in the coming weeks, which includes its GMP-validated 40mg and 60mg MDMA capsules.
This marks a pivotal milestone for OptimiHealth in its quest in collecting real-world evidence and patient-reported outcomes for MDMA-assisted therapy in patients with PTSD in Australia.
The company has also received an export permit from Health Canada to make its first shipment of validated GMP natural psilocybin extract to the Matai Medical Research Institute in New Zealand and will be used in a pilot study evaluating the feasibility, acceptability and safety of giving psychedelic-assisted therapies to healthy volunteers.
Based out of Vancouver, Optimi Health is a psychedelics pharmaceutical manufacturer licensed by Health Canada that focuses on controlled substances such as botanical psilocybin and MDMA.
Shares of Optimi Health Corp. (CSE:OPTI) are up 1.67 per cent to C$0.30 as of 10:05 am ET.
Join the discussion: Find out what everybody’s saying about this stock on the Optimi Health Corp. Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top image: Adobe Stock)
